Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of IBI3003 versus investigator's choice DPd or PVd in relapsed or refractory multiple myeloma
CTR20262035Phase 3Active
- Sponsor
- InnoCare Pharma
- Start
- Jun 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of IBI3003 in multiple myeloma (MM), sponsored by InnoCare Pharma. Started Jun 2026; status: active.
02
Drugs
IBI3003
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20262035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262035.